MONTE CARLO-BASED INVESTIGATION OF MICRODOSIMETRIC DISTRIBUTION OF HIGH ENERGY BRACHYTHERAPY SOURCES.

FLUKA-based Monte Carlo calculations were carried out to study microdosimetric distributions in air and in water for encapsulated high energy brachytherapy sources (60Co, 137Cs, 192Ir and 169Yb) by simulating a Tissue Equivalent Proportional Counter (Model LET1/2) having sensitive diameter of 1. 27 cm for a site size of 1 µm. The study also included microdosimetric distributions of bare sources. When the sources are in air, for a given source, the source geometry does not affect the y¯F and y¯D values significantly. When the encapsulated 192Ir, 137Cs and 60Co sources are in water, y¯F and y¯D values increase with distance in water which is due to degradation in the energy of photons. Using the calculated values of y¯D, relative biological effectiveness (RBE) was obtained for the investigated sources. When 60Co, 137Cs and 192Ir sources are in water, RBE increases from 1.03 ± 0.01 to 1.17 ± 0.01, 1.24 ± 0.01 to 1.46 ± 0.02 and 1.50 ± 0.01 to 1.75 ± 0.03, respectively, when the distance was increased from 3-15 cm, whereas for 169Yb, RBE is about 2, independent of distance in water.

Dosimetric comparison between realistic ocular model and other models for COMS plaque brachytherapy with 103Pd, 131Cs, and 125I radioisotopes.

Nowadays, Monte Carlo calculations are commonly used for the evaluation of dose distributions and dose volume histograms in eye brachytherapy. However, currently available eye models have simple geometries, and main substructures of the eye are either not defined in details or not distinguished at all. In this work absorbed doses of eye substructures have been estimated for eye plaque brachytherapy using the most realistic eye model available, and compared with absorbed doses obtained with other available eye models. For this, a medium-sized tumour on the left sides of the right eye was considered. Dosimetry calculations were performed for four different eye models developed based on a literature review, and using a 12 mm Collaborative Ocular Melanoma Study plaque containing 131Cs, 103Pd, and 125I sources. Obtained results illustrate that the estimated doses received by different eye substructures strongly depend on the model used to represent the eye. It is shown here that using a non-realistic eye model leads to a wrong estimation of doses for some eye substructures. For example, dose differences of up to 35% were observed between the models proposed by Nogueira and co-workers and Yoriyaz and co-workers, while doses obtained by use of the models proposed by Lesperance and co-workers, and Behrens and co-workers differed up to 100 and 63% as compared to the situation when a realistic model was used, respectively. Moreover, comparing different radionuclides showed that the most uniform dose distribution in the considered tumour region was that from 131Cs, with a coefficient of variation of 33%. In addition, considering the realistic eye model, it was found that the radiosensitive region of the lens received more than the threshold dose of cataract induction (0.5 Gy), for all investigated radionuclides.

Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II study.

PURPOSE: To compare quality of life (QoL) after brachytherapy with one of the three approved radioactive isotopes. METHODS AND MATERIALS: Patients with mostly favorable intermediate-risk prostate cancer were treated on this prospective phase II trial with brachytherapy as monotherapy, without hormonal therapy. QoL was recorded at baseline and each follow-up by using the Expanded Prostate Cancer Index Composite instrument. The minimal clinically important difference was defined as half the standard deviation of the baseline score for each domain. Mixed effect models were used to compare the different isotopes, and time-driven activity-based costing was used to compute costs. RESULTS: From 2006 to 2013, 300 patients were treated with iodine-125 (I-125, n = 98, prescribed dose [PD] = 145 Gy), palladium-103 (Pd-103, n = 102, PD = 125 Gy), or cesium-131 (Cs-131, n = 100, PD = 115 Gy). Median age was 64.9 years. Median follow-up time was 5.1 years for the entire cohort, and 7.1, 4.8 and 3.3 years for I-125, Pd-103, and Cs-131 groups, respectively. All three isotope groups showed an initial drop in QoL at first follow-up, which gradually improved over the first 2 years for urinary and bowel domains. QoL profiles were similar between I-125 and Pd-103, whereas Cs-131 showed a statistically significant decrease in QoL regarding bowel and sexual function at 12 months compared with Pd-103. However, these differences did not reach the minimal clinically important difference. Compared with I-125, the use of Pd-103 or Cs-131 resulted in cost increases of 18% and 34% respectively. CONCLUSIONS: The three different isotopes produced a similar QoL profile. Statistically significant differences favored Pd-103/I-125 over Cs-131 for bowel and sexual QoL, but this did not reach clinical significance.

The cost-effectiveness of surgical resection and cesium-131 intraoperative brachytherapy versus surgical resection and stereotactic radiosurgery in the treatment of metastatic brain tumors.

This study aims to evaluate the cost-effectiveness of surgical resection (S) and Cesium-131 (Cs-131) [S + Cs-131] intraoperative brachytherapy versus S and stereotactic radiosurgery (SRS) [S + SRS] for the treatment of brain metastases. Treatment records as well as hospital and outpatient charts of 49 patients with brain metastases between 2008 and 2012 who underwent S + Cs-131 (n = 24) and S + SRS (n = 25) were retrospectively reviewed. Hospital charges were compared for the single treatment in question. Means and curves of survival time were defined by the Kaplan-Meier estimator, with the cost analysis focusing on the time period of the relevant treatment. Quality adjusted life years (QALY) and Incremental cost-effectiveness ratios (ICER) were calculated for each treatment option as a measure of cost-effectiveness. The direct hospital costs of treatments per patient were: S + Cs131 = $19,271 and S + SRS = $44,219. The median survival times of S + Cs-131 and S + SRS were 15.5 and 11.3 months, and the 12 month survival rates were 61 % and 49 % (P = 0.137). The QALY for S + SRS when compared to S + Cs-131 yielded a p < 0.0001, making it significantly more cost-effective. The ICER also revealed that when compared to S + Cs-131, S + SRS was significantly inferior (p < 0.0001). S + Cs-131 is more cost-effective compared with S + SRS based on hospital charges as well as QALYs and ICER. Cost effectiveness, in addition to efficacy and risk, should factor into the comparison between these two treatment modalities for patients with surgically resectable brain metastases.

Monte Carlo dosimetric study of the medium dose rate CSM40 source.

The (137)Cs medium dose rate (MDR) CSM40 source model (Eckert & Ziegler BEBIG, Germany) is in clinical use but no dosimetric dataset has been published. This study aims to obtain dosimetric data for the CSM40 source for its use in clinical practice as required by the American Association of Physicists in Medicine (AAPM) and the European Society for Radiotherapy and Oncology (ESTRO). Penelope2008 and Geant4 Monte Carlo codes were used to characterize this source dosimetrically. It was located in an unbounded water phantom with composition and mass density as recommended by AAPM and ESTRO. Due to the low photon energies of (137)Cs, absorbed dose was approximated by collisional kerma. Additional simulations were performed to obtain the air-kerma strength, sK. Mass-energy absorption coefficients in water and air were consistently derived and used to calculate collisional kerma. Results performed with both radiation transport codes showed agreement typically within 0.05%. Dose rate constant, radial dose function and anisotropy function are provided for the CSM40 and compared with published data for other commercially available (137)Cs sources. An uncertainty analysis has been performed. The data provided by this study can be used as input data and verification in the treatment planning systems.

Perturbation of TG-43 parameters of the brachytherapy sources under insufficient scattering materials.

In the recommendations of Task Group #43 from American Association of Physicists in Medicine (AAPM TG43), methods of brachytherapy source dosimetry are recommended, under full scattering conditions. However, in actual brachytherapy procedures, sources may not be surrounded by full scattering tissue in all directions. Clinical examples include high-dose-rate (HDR) brachytherapy of the breast or low-dose-rate (LDR) brachytherapy of ocular melanoma using eye plaque treatment with 125I and 103Pd. In this work, the impact of the missing tissue on the TG-43-recommended dosimetric parameters of different brachytherapy sources was investigated. The impact of missing tissue on the TG-43-recommended dosimetric parameters of 137Cs, 192Ir, and 103Pd brachytherapy sources was investigated using the MCNP5 Monte Carlo code. These evaluations were performed by placing the sources at different locations inside a 30 × 30 × 30 cm3 cubical water phantom and comparing the results with the values of the source located at the center of the phantom, which is in a full scattering condition. The differences between the thickness of the overlying tissues for different source positions and the thickness of the overlying tissue in full scattering condition is referred to as missing tissue. The results of these investigations indicate that values of the radial dose function and 2D anisotropy function vary as a function of the thickness of missing tissue, only in the direction of the missing tissue. These changes for radial dose function were up to 5%, 11%, and 8% for 137Cs, 192Ir, and 103Pd, respectively. No significant changes are observed for the values of the dose rate constants. In this project, we have demonstrated that the TG-43 dosimetric parameters may only change in the directions of the missing tissue. These results are more practical than the published data by different investigators in which a symmetric effect of the missing tissue on the dosimetric parameters of brachytherapy source are being considered, regardless of the implant geometry in real clinical cases.

Patient release criteria for low dose rate brachytherapy implants.

A lack of consensus regarding a model governing the release of patients following sealed source brachytherapy has led to a set of patient release policies that vary from institution to institution. The U.S. Nuclear Regulatory Commission has issued regulatory guidance on patient release in NUREG 1556, Volume 9, Rev. 2, Appendix U, which allows calculation of release limits following implant brachytherapy. While the formalism presented in NUREG is meaningful for the calculation of release limits in the context of relatively high energy gamma emitters, it does not estimate accurately the effective dose equivalent for the common low dose rate brachytherapy sources Cs, I, and Pd. NUREG 1556 states that patient release may be based on patient-specific calculations as long as the calculation is documented. This work is intended to provide a format for patient-specific calculations to be used for the consideration of patients' release following the implantation of certain low dose rate brachytherapy isotopes.

Comparison of 16 mm OSU-Nag and COMS eye plaques.

OSU-NAG eye plaques use fewer sources than COMS-plaques of comparable size, and do not employ a Silastic seed carrier insert. Monte Carlo modeling was used to calculate 3D dose distributions for a 16 mm OSU-NAG eye plaque and a 16 mm COMS eye plaque loaded with either Iodine-125 or Cesium-131 brachytherapy sources. The OSU-NAG eye plaque was loaded with eight sources forming two squares, whereas the COMS eye plaque was loaded with thirteen sources approximating three isocentric circles. A spherical eyeball 24.6 mm in diameter and an ellipsoid-like tumor 6 mm in height and 12 mm in the major and minor axes were used to evaluate the doses delivered. To establish a fair comparison, a water seed carrier was used instead of the Silastic seed carrier designed for the traditional COMS eye plaque. Calculations were performed on the dose distributions along the eye plaque axis and the DVHs of the tumor, as well as the 3D distribution. Our results indicated that, to achieve a prescription dose of 85 Gy at 6 mm from the inner sclera edge for a six-day treatment, the OSU-NAG eye plaque will need 6.16 U/source and 6.82U/source for 125I and 131Cs, respectively. The COMS eye plaque will require 4.02 U/source and 4.43 U/source for the same source types. The dose profiles of the two types of eye plaques on their central axes are within 9% difference for all applicable distances. The OSU-NAG plaque delivers about 10% and 12% more dose than the COMS for 125I and 131Cs sources, respectively, at the inner sclera edge, but 6% and 3% less dose at the opposite retina. The DVHs of the tumor for two types of plaques were within 6% difference. In conclusion, the dosimetric quality of the OSU-NAG eye plaque used in eye plaque brachytherapy is comparable to the COMS eye plaque.

Impact of the vaginal applicator and dummy pellets on the dosimetry parameters of Cs-137 brachytherapy source.

In this study, dose rate distribution around a spherical 137Cs pellet source, from a low-dose-rate (LDR) Selectron remote afterloading system used in gynecological brachytherapy, has been determined using experimental and Monte Carlo simulation techniques. Monte Carlo simulations were performed using MCNP4C code, for a single pellet source in water medium and Plexiglas, and measurements were performed in Plexiglas phantom material using LiF TLD chips. Absolute dose rate distribution and the dosimetric parameters, such as dose rate constant, radial dose functions, and anisotropy functions, were obtained for a single pellet source. In order to investigate the effect of the applicator and surrounding pellets on dosimetric parameters of the source, the simulations were repeated for six different arrangements with a single active source and five non-active pellets inside central metallic tubing of a vaginal cylindrical applicator. In commercial treatment planning systems (TPS), the attenuation effects of the applicator and inactive spacers on total dose are neglected. The results indicate that this effect could lead to overestimation of the calculated F(r,θ), by up to 7% along the longitudinal axis of the applicator, especially beyond the applicator tip. According to the results obtained in this study, in a real situation in treatment of patients using cylindrical vaginal applicator and using several active pellets, there will be a large discrepancy between the result of superposition and Monte Carlo simulations.

Sensitivity of low energy brachytherapy Monte Carlo dose calculations to uncertainties in human tissue composition.

PURPOSE: The objective of this work is to assess the sensitivity of Monte Carlo (MC) dose calculations to uncertainties in human tissue composition for a range of low photon energy brachytherapy sources: 125I, 103Pd, 131Cs, and an electronic brachytherapy source (EBS). The low energy photons emitted by these sources make the dosimetry sensitive to variations in tissue atomic number due to the dominance of the photoelectric effect. This work reports dose to a small mass of water in medium D(w,m) as opposed to dose to a small mass of medium in medium D(m,m). METHODS: Mean adipose, mammary gland, and breast tissues (as uniform mixture of the aforementioned tissues) are investigated as well as compositions corresponding to one standard deviation from the mean. Prostate mean compositions from three different literature sources are also investigated. Three sets of MC simulations are performed with the GEANT4 code: (1) Dose calculations for idealized TG-43-like spherical geometries using point sources. Radial dose profiles obtained in different media are compared to assess the influence of compositional uncertainties. (2) Dose calculations for four clinical prostate LDR brachytherapy permanent seed implants using 125I seeds (Model 2301, Best Medical, Springfield, VA). The effect of varying the prostate composition in the planning target volume (PTV) is investigated by comparing PTV D90 values. (3) Dose calculations for four clinical breast LDR brachytherapy permanent seed implants using 103Pd seeds (Model 2335, Best Medical). The effects of varying the adipose/gland ratio in the PTV and of varying the elemental composition of adipose and gland within one standard deviation of the assumed mean composition are investigated by comparing PTV D90 values. For (2) and (3), the influence of using the mass density from CT scans instead of unit mass density is also assessed. RESULTS: Results from simulation (1) show that variations in the mean compositions of tissues affect low energy brachytherapy dosimetry. Dose differences between mean and one standard deviation of the mean composition increasing with distance from the source are observed. It is established that the 125I and 131Cs sources are the least sensitive to variations in elemental compositions while 103Pd is most sensitive. The EBS falls in between and exhibits complex behavior due to significant spectral hardening. Results from simulation (2) show that two prostate compositions are dosimetrically equivalent to water while the third shows D90 differences of up to 4%. Results from simulation (3) show that breast is more sensitive than prostate with dose variations of up to 30% from water for 70% adipose/30% gland breast. The variability of the breast composition adds a +/- 10% dose variation. CONCLUSIONS: Low energy brachytherapy dose distributions in tissue differ from water and are influenced by density, mean tissue composition, and patient-to-patient composition variations. The results support the use of a dose calculation algorithm accounting for heterogeneities such as MC. Since this work shows that variations in mean tissue compositions affect MC dosimetry and result in increased dose uncertainties, the authors conclude that imaging tools providing more accurate estimates of elemental compositions such as dual energy CT would be beneficial.

[Economic assessment of pulsed dose-rate (PDR) brachytherapy with optimized dose distribution for cervix carcinoma]. / Evaluation économique de la curiethérapie de débit pulsé gynécologique (PDR) avec optimisation de la dose pour les cancers du col utérin.

PURPOSE: Our study aims at evaluating the cost of pulsed dose-rate (PDR) brachytherapy with optimized dose distribution versus traditional treatments (iridium wires, cesium, non-optimized PDR). Issues surrounding reimbursement were also explored. MATERIALS AND METHODS: This prospective, multicentre, non-randomised study conducted in the framework of a project entitled "Support Program for Costly Diagnostic and Therapeutic Innovations" involved 21 hospitals. Patients with cervix carcinoma received either classical brachytherapy or the innovation. The direct medical costs of staff and equipment, as well as the costs of radioactive sources, consumables and building renovation were evaluated from a hospital point of view using a microcosting approach. Subsequent costs per brachytherapy were compared between the four strategies. RESULTS: The economic study included 463 patients over two years. The main resources categories associated with PDR brachytherapy (whether optimized or not) were radioactive sources (1053euro) and source projectors (735euro). Optimized PDR induced higher cost of imagery and dosimetry (respectively 130euro and 367euro) than non-optimized PDR (47euro and 75euro). Extra costs of innovation over the less costly strategy (iridium wires) reached more than 2100euro per treatment, but could be reduced by half in the hypothesis of 40 patients treated per year (instead of 24 in the study). CONCLUSION: Aside from staff, imaging and dosimetry, the current hospital reimbursements largely underestimated the cost of innovation related to equipment and sources.

A comprehensive dosimetric comparison between (131)Cs and (125)I brachytherapy sources for COMS eye plaque implant.

PURPOSE: To verify the dosimetric characteristics of (131)Cs source in the Collaborative Ocular Melanoma Study (COMS) eye plaque brachytherapy, to compare (131)Cs with (125)I in a sample implant, and to examine the accuracy of treatment planning system in dose calculation. METHODS AND MATERIALS: Monte Carlo (MC) technique was used to generate three-dimensional dose distributions of a 16-mm COMS eye plaque loaded with (131)Cs and (125)I brachytherapy sources separately. A spherical eyeball, 24.6mm in diameter, and an ellipsoidal tumor, 6mm in height and 12mm in diameter, were used to evaluate the doses delivered. The simulations were carried out both with and without the gold and gold alloy plaque. A water-equivalent seed carrier was used instead of the silastic insert designed for the traditional COMS eye plaque. The 13 sources involved were also individually simulated to evaluate the intersource effect. In addition, a treatment planning system was used to calculate the doses at the central axis for comparison with MC data. RESULTS: The gold plaque had significantly reduced the dose in the tumor volume; at the prescription point of this study, that is, 6mm from the edge of inner sclera, the gold plaque reduced the dose by about 7% for both types of (131)Cs and (125)I sources, but the gold alloy plaque reduced the dose only by 4% for both types of sources. The intersource effect reduced the dose by 2% for both types of sources. At the same prescription dose, the treatment with the gold plaque applicator tended to create more hot regions for either type of sources than were seen with the homogeneous water phantom. The doses of TPS agree with the MC. CONCLUSION: The (131)Cs source is comparable to the (125)I source in the eye plaque brachytherapy. The TPS can provide accurate dose calculations for eye plaque implants with either type of sources.

EGSnrc-based Monte Carlo dosimetry of CSA1 and CSA2 137Cs brachytherapy source models.

PURPOSE: AAPM TG-56 recommends the use of a specific dosimetric dataset for each brachytherapy source model. In this study, a full dosimetric dataset for indigenously developed 137Cs source models, namely, the CSA1 and CSA2, in accordance with the AAPM TG-43U1 formalism is presented. The study includes calculation of dose-to-kerma ratio D/K in water around these sources including stainless steel encapsulated 137Cs sources such as RTR, 3M, and selectron/LDR 137Cs. METHODS: The Monte Carlo-based EGSnrcMP code system is employed for modeling the sources in vacuum and in water. Calculations of air-kerma strength, S(K) for the investigated sources and collision kerma in water along the transverse axis of the RTR source are based on the FLURZnrc code. Simulations of water-kerma and dose in water for the CSA1, CSA2, RTR, 3M, and selectron/ LDR 137Cs sources are carried out using the DOSRZnrc code. In DOSRZnrc calculations, water-kerma and dose are scored in a cylindrical water phantom having dimensions of 80 cm diameter x 80 cm height. RESULTS: The calculated dose-rate constants for the CSA1 and CSA2 sources are 0.945(1) and 1.023(1) cGy/(h U), respectively. The calculated value of S(K) per unit source activity, S(K)/A for the CSA1 and CSA2 sources is 7.393(7) x 10(-8) cGy cm2/(h Bq). The EGSnrcMP-based collision kerma rates for the RTR source along the transverse axis (0.25-10 cm) agree with the corresponding GEANT4-based published values within 0.5%. Anisotropy profiles of the CSA1 and CSA2 sources are significantly different from those of other sources. For the selectron/LDR single pellet 137Cs spherical source (modeled as a cylindrical pellet with dimensions similar to the seed selectron), the values of D/K at 1 and 1.25 mm from the capsule are 1.023(1) and 1.029(1), respectively. The value of D/K at 1 mm from the CSA1, CSA2, RTR, and 3M 137Cs source capsules (all sources have an external radius of 1.5 mm) is 1.017(1) and this ratio is applicable to axial positions z = 0 to z = -L/2. This is in contrast to a published GEANT4-based Monte Carlo dosimetric study on RTR and 3M 137Cs sources wherein the authors have assumed that collision kerma is approximately equal to absorbed dose at 1 mm from the source capsules. Collision kerma is approximately equal to absorbed dose for distances > or = 2 mm from source capsules as opposed to > or = 1 mm reported in published studies. A detailed electron transport is necessary up to 2 mm from source capsules. CONCLUSIONS: The Monte Carlo-calculated dose-rate data for the CSA1 and CSA2 sources can be used as input data for treatment planning or to verify the calculations by radiotherapy treatment planning system.

Comparison of a 3-D multi-group SN particle transport code with Monte Carlo for intracavitary brachytherapy of the cervix uteri.

A patient dose distribution was calculated by a 3D multi-group S N particle transport code for intracavitary brachytherapy of the cervix uteri and compared to previously published Monte Carlo results. A Cs-137 LDR intracavitary brachytherapy CT data set was chosen from our clinical database. MCNPX version 2.5.c, was used to calculate the dose distribution. A 3D multi-group S N particle transport code, Attila version 6.1.1 was used to simulate the same patient. Each patient applicator was built in SolidWorks, a mechanical design package, and then assembled with a coordinate transformation and rotation for the patient. The SolidWorks exported applicator geometry was imported into Attila for calculation. Dose matrices were overlaid on the patient CT data set. Dose volume histograms and point doses were compared. The MCNPX calculation required 14.8 hours, whereas the Attila calculation required 22.2 minutes on a 1.8 GHz AMD Opteron CPU. Agreement between Attila and MCNPX dose calculations at the ICRU 38 points was within +/- 3%. Calculated doses to the 2 cc and 5 cc volumes of highest dose differed by not more than +/- 1.1% between the two codes. Dose and DVH overlays agreed well qualitatively. Attila can calculate dose accurately and efficiently for this Cs-137 CT-based patient geometry. Our data showed that a three-group cross-section set is adequate for Cs-137 computations. Future work is aimed at implementing an optimized version of Attila for radiotherapy calculations.

Thermoluminescence dosimetry measurements of brachytherapy sources in liquid water.

Radiation therapy dose measurements are customarily performed in liquid water. The characterization of brachytherapy sources is, however, generally based on measurements made with thermoluminescence dosimeters (TLDs), for which contact with water may lead to erroneous readings. Consequently, most dosimetry parameters reported in the literature have been based on measurements in water-equivalent plastics, such as Solid Water. These previous reports employed a correction factor to transfer the dose measurements from a plastic phantom to liquid water. The correction factor most often was based on Monte Carlo calculations. The process of measuring in a water-equivalent plastic phantom whose exact composition may be different from published specifications, then correcting the results to a water medium leads to increased uncertainty in the results. A system has been designed to enable measurements with TLDs in liquid water. This system, which includes jigs to support water-tight capsules of lithium fluoride in configurations suitable for measuring several dosimetric parameters, was used to determine the correction factor from water-equivalent plastic to water. Measurements of several 125I and 131Cs prostate brachytherapy sources in liquid water and in a Solid Water phantom demonstrated a correction factor of 1.039 +/- 0.005 at 1 cm distance. These measurements are in good agreement with a published value of this correction factor for an 125I source.

Dosimetric characterization of model Cs-1 Rev2 cesium-131 brachytherapy source in water phantoms and human tissues with MCNP5 Monte Carlo simulation.

A recently developed alternative brachytherapy seed, Cs-1 Rev2 cesium-131, has begun to be used in clinical practice. The dosimetric characteristics of this source in various media, particularly in human tissues, have not been fully evaluated. The aim of this study was to calculate the dosimetric parameters for the Cs-1 Rev2 cesium-131 seed following the recommendations of the AAPM TG-43U1 report [Rivard et al., Med. Phys. 31, 633-674 (2004)] for new sources in brachytherapy applications. Dose rate constants, radial dose functions, and anisotropy functions of the source in water, Virtual Water, and relevant human soft tissues were calculated using MCNP5 Monte Carlo simulations following the TG-43U1 formalism. The results yielded dose rate constants of 1.048, 1.024, 1.041, and 1.044 cGy h(-1) U(-1) in water, Virtual Water, muscle, and prostate tissue, respectively. The conversion factor for this new source between water and Virtual Water was 1.02, between muscle and water was 1.006, and between prostate and water was 1.004. The authors' calculation of anisotropy functions in a Virtual Water phantom agreed closely with Murphy's measurements [Murphy et al., Med. Phys. 31, 1529-1538 (2004)]. Our calculations of the radial dose function in water and Virtual Water have good agreement with those in previous experimental and Monte Carlo studies. The TG-43U1 parameters for clinical applications in water, muscle, and prostate tissue are presented in this work.

Multiple-estimate monte carlo calculation of the dose rate constant for a cesium-131 interstitial brachytherapy seed.

The purpose of this study was to calculate a more accurate dose rate constant for the 131Cs (model CS-1, IsoRay Medical, Inc., Richland, WA) interstitial brachytherapy seed. Previous measurements of the dose rate constant for this seed have been reported by others with incongruity. Recent direct measurements by thermoluminescence dosimetry and by gamma-ray spectroscopy were about 15% greater than earlier thermoluminescence dosimetry measurements. Therefore, we set about to calculate independent values by a Monte Carlo approach that combined three estimates as a consistency check, and to quantify the computational uncertainty. The calculated dose rate constant for the 131Cs seed was 1.040 cGy h(-1) U(-1) for an ionization chamber model and 1.032 cGy h(-1) U(-1) for a circular ring model. A formal value of 2.2% uncertainty was calculated for both values. The range of our multiestimate values were from 1.032 to 1.061 cGy h(-1) U(-1). We also modeled three 125I seeds with known dose rate constants to test the accuracy of this study's approach.

Dose rate constant of a cesium-131 interstitial brachytherapy seed measured by thermoluminescent dosimetry and gamma-ray spectrometry.

The aim of this work was to conduct an independent determination of the dose rate constant of the newly introduced Model CS-1 131Cs seed. A total of eight 131Cs seeds were obtained from the seed manufacturer. The air-kerma strength of each seed was measured by the manufacturer whose calibration is traceable to the air-kerma strength standard established for the 131Cs seeds at the National Institute of Standards and Technology (1 sigma uncertainty < 1%). The dose rate constant of each seed was measured by two independent methods: One based on the actual photon energy spectrum emitted by the seed using gamma-ray spectrometry and the other based on the dose-rate measured by thermoluminescent dosimeter (TLD) in a Solid Water phantom. The dose rate constant in water determined by the gamma-ray spectrometry technique and by the TLD dosimetry are 1.066 +/- 0.064 cGyh(-1)U(-1) and 1.058 +/- 0.106 cGyh(-1)U(-1), respectively, showing excellent agreement with each other. These values, however, are approximately 15% greater than a previously reported value of 0.915 cGyh(-1)U(-1) [Med. Phys. 31, 1529-1538 (2004)]. Although low-energy fluorescent x rays at 16.6 and 18.7 keV, originating from niobium present in the seed construction, were measured in the energy spectrum of the 131Cs seeds, their yields were not sufficient to lower the dose rate constant to the value of 0.915 cGyh(-1)U(-1). Additional determinations of the dose rate constant may be needed to establish an AAPM recommended consensus value for routine clinical use of the 131Cs seed.

Technical note: Monte Carlo derivation of TG-43 dosimetric parameters for radiation therapy resources and 3M Cs-137 sources.

In clinical brachytherapy dosimetry, a detailed dose rate distribution of the radioactive source in water is needed in order to plan for quality treatment. Two Cs-137 sources are considered in this study; the Radiation Therapy Resources 67-800 source (Radiation Therapy Resources Inc., Valencia, CA) and the 3M model 6500/6D6C source. A complete dosimetric dataset for both sources has been obtained by means of the Monte Carlo GEANT4 code. Dose rate distributions are presented in two different ways; following the TG43 formalism and in a 2D rectangular dose rate table. This 2D dose rate table is helpful for the TPS quality control and is fully consistent with the TG43 dose calculation formalism. In this work, several improvements to the previously published data for these sources have been included: the source asymmetries were taken explicitly into account in the MC calculations, TG43 data were derived directly from MC calculations, the data radial range was increased, the angular grid in the anisotropy function was increased, and TG43 data is now consistent with the along and away dose rate table as recommended by the TG43 update.